We are live on ! Find out more
NGNE icon

Neurogene

74 hedge funds and large institutions have $417M invested in Neurogene in 2020 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 12

108% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 13

61% more capital invested

Capital invested by funds: $259M → $417M (+$158M)

23% more funds holding

Funds holding: 6074 (+14)

0.3% more ownership

Funds ownership: 2.96%3.27% (+0.3%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

31% less call options, than puts

Call options by funds: $387K | Put options by funds: $564K

Holders
74
Holders Change
+14
Holders Change %
+23.33%
% of All Funds
1.52%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
27
Increased
27
Reduced
12
Closed
13
Calls
$387K
Puts
$564K
Net Calls
-$177K
Net Calls Change
-$809K

NGNE Hedge Fund Activity: Q2 2020 in Review

74 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q2 2020, worth a combined $417M — up 61% from $259M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new NGNE positions and 13 closed out — a net gain of 14 holders — while 27 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $20.6M. The largest seller was OrbiMed, exiting entirely with an estimated $10.5M sold.

  • 74 institutional investors held Neurogene (NGNE) as of Q2 2020, up from 60 in Q1 2020.
  • Funds reported $417M of Neurogene stock for Q2 2020, up 61% quarter-over-quarter.
  • 27 funds opened new Neurogene positions in Q2 2020 and 13 closed out, a net change of +14 holders.
  • The largest Neurogene buyer in Q2 2020 was BlackRock, an estimated $20.6M added.
  • The largest Neurogene seller in Q2 2020 was OrbiMed, an estimated $10.5M sold.

Based on aggregated 13F filings for Q2 2020.